Alon Ben-Noon, CEO and co-founder of NeuroSense Therapeutics, a clinical-stage biotechnology company focused on treatments for neurodegenerative diseases discusses the recent FDA clearance to initiate a pharmacokinetic study of PrimeC, a novel extended-release formulation composed of unique doses of two FDA-approved drugs, which aims to synergistically target several key mechanisms of amyotrophic lateral sclerosis (ALS) that contribute to motor neuron degeneration. NeuroSense plans to initiate a Phase 2b clinical trial multicentered in Israel, the US, and Europe in the first half of 2022 to evaluate the final formulation of PrimeC.
Co-Founder and CEO of NeuroSense Therapeutics.
Prior to the establishment of NeuroSense, Alon founded MediCan Consulting, a successful consultancy firm which worked and collaborated with many leading pharmaceutical R&D companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. The firm’s diligent employees were pioneers, who paved the way to more efficient and accurate work in the industry, mainly in small biotech companies, while coordinating innovative Drug Development Programs, managing operational activities and involved in business development activities.
MBA and BSc in Industrial Engineering, both from Ben-Gurion University